Atenolol vs nonatenolol β-blockers for the treatment of hypertension: A meta-analysis

Canadian Journal of Cardiology

Volumn 30, Issue 5 S, 2014, Pages

  Kuyper, Laura M ^a   Khan, Nadia A ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Center for Health Evaluation and Outcome Sciences   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; OXPRENOLOL; PROPRANOLOL;

ANTIHYPERTENSIVE THERAPY; AORTA PRESSURE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG INDICATION; HEART INFARCTION; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; REVIEW; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ATENOLOL; CALCIUM CHANNEL BLOCKERS; CANADA; HUMANS; HYPERTENSION; INCIDENCE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

EID: 84898896116     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.01.006     Document Type: Review

References (40)

1. Poirier L., Lacourciere Y. The evolving role of beta-adrenergic receptor blockers in managing hypertension. Can J Cardiol 2012, 28:334-340.
2. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998, 279:1903-1907.
3. Khan N., McAlister F.A. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006 Jun 6, 174(12):1737-1742. PubMed PMID: 16754904.
4. Biccard B.M., Sear J.W., Foex P. Are lipophilic beta-blockers preferable for peri-operative cardioprotection?. SAfr J Anaesth Analg 2006, 12:141-146.
5. Schiffrin E.L., Deng L.Y., Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 1994, 23:83-91.
6. Neutel J.M., Schnaper H., Cheung D.G., Graettinger W.F., Weber M.A. Antihypertensive effects of beta blockers administered once daily: 24-hour measurements. Am Heart J 1990, 120:166-171.
7. Bangalore S., Parkar S., Grossman E., Messerli F.H. Ameta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007, 100:1254-1262.
8. Wiysonge C.S., Bradley H.A., Volmink J., Mayosi B.M., Mbewu A., Opie L.H. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012, 8:CD002003.
9. Dahlof B., Lindholm L.H., Hansson L. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285.
10. Hansson L., Lindholm L.H., Ekbom T. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999, 354:1751-1756.
11. Hansson L., Lindholm L.H., Niskanen L. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
12. Hansson L., Hedner T., Lund-Johansen P. Randomised trial of effects of calcium antagonists compared with diuretics and beta blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365.
13. Black H.R., Elliott W.J., Grandits G. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
14. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. MRC Working Party. BMJ 1985, 291:97-104.
15. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992, 304:405-412.
16. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. The Dutch TIA Trial Study Group. Stroke 1993, 24:543-548.
17. Coope J., Warrender T.S. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986, 293:1145-1151.
18. Eriksson S., Olofsson B.-O., Wester P.-O. Atenolol in secondary prevention after stroke. The TEST Study Group. Cerebrovasc Dis 1995, 5:21-25.
19. Cardiovascular risk and risk factors in a randomised trial of treatment based on the beta-blockers oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). The IPPPSH Collaborative Group. JHypertens 1985, 3:379-392.
20. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. Results of long-term therapy. JAMA 1982, 248:2004-2011.
21. Berglund G., Andersin O., Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. Acta Med Scand 1986, 220:419-424.
22. Wilhelmsen L., Berglund G., Elmfeldt D. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. JHypertens 1987, 5:561-572.
23. Yurenev A.P., Dyakonova H.G., Novikov I.D. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992, 6:182S-189S.
24. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998, 317:713-720.
25. Dahlof B., Devereux R.B., Kjeldsen S.E. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
26. Wright J.T., Bakris G.L., Greene T. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK trial. JAMA 2002, 288:2421-2431.
27. Zanchetti A., Bond M.G., Henning M. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002, 106:2422-2427.
28. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. Acalcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003, 290:2805-2816.
29. Dahlof B., Sever P.S., Poulter N.R. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
30. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-1553.
31. Franklin S.S. Elderly hypertensives: how are they different?. JAm Soc Hypertens 2012, 14:779-786.
32. Tabriziani H., Steiner J., Papademetriou V. Dilemmas in treating hypertension in octogenerians. JAm Soc Hypertens 2012, 14:711-717.
33. Cohen D.L., Townsend R.R. Update on pathophysiology and treatment of hypertension in the elderly. Curr Hypertens Rep 2011, 13:330-337.
34. Chobanian A.V. Isolated systolic hypertension in the elderly. NEngl J Med 2007, 357:789-796.
35. Dudenbostel T., Glasser S.P. Effects of antihypertensive drugs on arterial stiffness. Cardiol Rev 2012, 20:259-263.
36. Mahmud A., Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008, 21:663-667.
37. The CAFÉ Investigators; for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006;113:1213-25.
38. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National High Blood Pressure Education Program. Bethesda, MD, National Heart, Lung, and Blood Institute; 2004; Report No. 04-5230.
39. Hypertension: the clinical management of primary hypertension in adults. Update of Clinical Guidelines 18 and 34 [Internet]; 2011. National Clinical Guideline Centre (UK). London Royal College of Physicians (UK). National Institute for Health and Clinical Excellence.
40. Hackam D.G., Quinn R.R., Ravani P., et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013, 29:528-542. Canadian Hypertension Education Program.